1 |
Potent and specific inhibition of glycosidases by small artificial binding proteins (affitins). PLoS One. 2014 May 13;9(5):e97438.
|
2 |
A novel, smaller scaffold for Affitins: Showcase with binders specific for EpCAM. Biotechnol Bioeng. 2018 Feb;115(2):290-299.
|
3 |
Tolerance of the archaeal Sac7d scaffold protein to alternative library designs: characterization of anti-immunoglobulin G Affitins. Protein Eng Des Sel. 2013 Apr;26(4):267-75.
|
4 |
Whole-bacterium ribosome display selection for isolation of highly specific anti-Staphyloccocus aureus Affitins for detection- and capture-based biomedical applications. Biotechnol Bioeng. 2019 Aug;116(8):1844-1855.
|
5 |
Phage display selection of tight specific binding variants from a hyperthermostable Sso7d scaffold protein library.FEBS J. 2016 Apr;283(7):1351-67.
|
6 |
Affinity transfer to the archaeal extremophilic Sac7d protein by insertion of a CDR. Protein Eng Des Sel. 2014 Oct;27(10):431-8.
|
7 |
Use of the Nanofitin Alternative Scaffold as a GFP-Ready Fusion Tag. PLoS One. 2015 Nov 5;10(11):e0142304.
|
8 |
Characterization of Affitin proteolytic digestion in biorelevant media and improvement of their stabilities via protein engineering. Sci Rep. 2020 Nov 12;10(1):19703.
|
9 |
Switching an anti-IgG binding site between archaeal extremophilic proteins results in Affitins with enhanced pH stability. J Biotechnol. 2014 Dec 20;192 Pt A:123-9.
|
10 |
Artificial binding proteins (Affitins) as probes for conformational changes in secretin PulD. J Mol Biol. 2008 Nov 28;383(5):1058-68.
|
11 |
Remodeling a DNA-binding protein as a specific in vivo inhibitor of bacterial secretin PulD. Proc Natl Acad Sci U S A. 2007 Nov 13;104(46):17983-8.
|
12 |
Nanofitin as a New Molecular-Imaging Agent for the Diagnosis of Epidermal Growth Factor Receptor Over-Expressing Tumors. Bioconjug Chem. 2017 Sep 20;28(9):2361-2371.
|
13 |
Reagentless fluorescent biosensors from artificial families of antigen binding proteins. Biosens Bioelectron. 2011 Jun 15;26(10):4184-90.
|
14 |
Nanofitins targeting heat shock protein 110: An innovative immunotherapeutic modality in cancer. Int J Cancer. 2021 Jun 15;148(12):3019-3031.
|